Mifamurtide acid
As of the edition of 20 October 2026, Mifamurtide acid is a small molecule: marketed, first approved in 2009 (EU); acts on NOD2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Mepact
- First approved
- 6 March 2009 (EU)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- TAKEDA PHARMA LTDA.; 2 holders in all
- Registered trials
- 7, 2 stopped early
- Disease areas
- Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NOD2 | Nucleotide-binding oligomerization domain-containing protein 2 | Q9HC29 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 0 | 1 |
| Phase 2 | 4 | 1 | 2 | 1 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Esteve Pharmaceuticals | Applicant | 2009 to now |